A Phase 2/3 interventional study of Vasopressin, Arginine and Methylprednisolone in Heart Arrest, sponsored by Lars Wiuff Andersen. Completed at 10 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-02.
Sponsored by Lars Wiuff Andersen · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Heart Arrest with a site in Denmark — 6 open to participants now, 11 under way, none of them phase 3. Heart Arrest · Denmark.
Among the 36 studies in Heart Arrest with a site in Denmark, this one is the 11th largest by enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2018, is the only one in phase 2/3, and was the 17th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →6 of the 36 studies in Heart Arrest with a site in Denmark are open now. Recruiting first, the newest first:
University of Aarhus · Sites in Denmark
Ages 18+
Lars Wiuff Andersen · Sites in Denmark
Ages 18+
University of Aarhus · Sites in Denmark, Norway
Ages 18+
Rigshospitalet, Denmark · Sites in Denmark
Ages 18–65
Emergency Medical Services, Capital Region, Denmark · Sites in Denmark
Ages 8+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 1 · Phase 4 5
First in 2007; this study’s year is marked. 7 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 501 is above the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 274 across the 26 interventional studies, 157 across the 10 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 36 has an industry lead sponsor. The 10 most frequent:
Lars Wiuff Andersen is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Lars Wiuff Andersen has 4 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Arrest with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04446585Emergency Medical Services, Capital Region, DenmarkCardiac Arrest in Residential Areas With Mobile First-responder Activation | 2027-01 |
| NCT06809309University of AarhusThe Ventilation During In-hospital Cardiac Arrest Study | 2027-04 |
| NCT05173740Rigshospitalet, DenmarkRehabilitation for Survivors of Out-of-hospital Cardiac Arrest | 2027-07-31 |
| NCT06979700University of AarhusEarly WAKE-up Predictors After Out-of-Hospital Cardiac Arrest | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies in Heart Arrest with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of vasopressin and methylprednisolone during adult in-hospital cardiac arrest. There will be ten enrolling sites in Denmark. 492 adult patients with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).
Drug: Vasopressin, Arginine · Drug: Methylprednisolone
The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl ("normal saline") from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl.
Drug: NaCl
20 IE of vasopressin per dose for a maximum of four doses (80 IU)
40 mg methylprednisolone once
Placebo
Number of Participants With Return of Spontaneous Circulation
Return of spontaneous circulation is defined as spontaneous circulation with no further need for chest compressions sustained for at least 20 minutes
Time frame: During the cardiac arrest, an average of 20 minutes
Number of Participants That Survived 30 Days
Time frame: At 30 days
Number of Participants With a Favorable Neurological Outcome at 30 Days
A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.
Time frame: At 30 days
Vasopressor-free Days
Vasopressor-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving vasopressors and is alive.
Time frame: 7 days
Invasive Ventilation-free Days
Invasive ventilation-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving invasive ventilation and is alive.
Time frame: 7 days
Sequential Organ Failure Assessment (SOFA) Score at 24, 48 and 72 Hours
The SOFA score is a validated and widely used measure of organ failure assessing the respiratory, nervous, cardiovascular, hepatic, coagulation, and renal systems. We will assess both the cardiovascular sub score as well as the overall SOFA score.
Time frame: 24, 48 and 72 hours
Hospital Disposition
Hospital disposition (e.g. home, rehabilitation, nursing home, hospice) will be defined at the time of discharge from the initial acute care hospital.
Time frame: At hospital discharge, up to 1 year
Survival
Time frame: At 90 days, 180 days, and 1 year
Favorable Neurological Outcome
A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.
Time frame: At 90 days, 180 days, and 1 year
Modified Rankin Scale (mRS)
The mRS is a 7-point scale, ranging from 0 (no symptoms) to 6 (dead), assessing the degree of disability and dependence after a neurological injury such as stroke or cardiac arrest. A good outcome will be defined as a mRS of 0 to 3 and a poor outcome as 4 to 6.
Time frame: At 30 days, 90 days, 180 days, and 1 year
Glasgow Outcome Scale Extended (GOSE)
The GOSE is a 8-point scale that is an extension of the Glasgow Outcomes Scale (which is identical to the CPC, only with inverse scores) where the scores 1, 2 and 3 from the CPC score is divided into two.
Time frame: At 30 days, 90 days, 180 days, and 1 year
Health-related Quality of Life (EQ-5D-5L)
The EQ-5D-5L is a well-established measure of health-related quality of life that is quantified as a utility (i.e. a measure of quality of life between 0 and 1).
Time frame: At 30 days, 90 days, 180 days, and 1 year
| Milestone | Vasopressin and Methylprednisolone | Placebo |
|---|---|---|
| Started | 237 | 264 |
| Completed | 237 | 264 |
| Not completed | 0 | 0 |
Return of spontaneous circulation is defined as spontaneous circulation with no further need for chest compressions sustained for at least 20 minutes
| participants | Vasopressin and Methylprednisolone | Placebo |
|---|---|---|
| Number of Participants With Return of Spontaneous Circulation | 100 | 86 |
| Participants | Vasopressin and Methylprednisolone | Placebo |
|---|---|---|
| Number of Participants That Survived 30 Days | 23 | 31 |
A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.
| Participants | Vasopressin and Methylprednisolone | Placebo |
|---|---|---|
| Number of Participants With a Favorable Neurological Outcome at 30 Days | 18 | 20 |
Vasopressor-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving vasopressors and is alive.
Results for this outcome have not been posted.
Invasive ventilation-free days will be defined as the number of days within the first 7 days after the cardiac arrest where the patient is not receiving invasive ventilation and is alive.
Results for this outcome have not been posted.
The SOFA score is a validated and widely used measure of organ failure assessing the respiratory, nervous, cardiovascular, hepatic, coagulation, and renal systems. We will assess both the cardiovascular sub score as well as the overall SOFA score.
Results for this outcome have not been posted.
Hospital disposition (e.g. home, rehabilitation, nursing home, hospice) will be defined at the time of discharge from the initial acute care hospital.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
A favorable neurological outcome will be defined as a cerebral performance category score of 1 or 2. The cerebral performance category score is a 5-point scale assessing neurological/functional outcomes after brain damage with higher scores indicating worse neurological/functional outcomes.
Results for this outcome have not been posted.
The mRS is a 7-point scale, ranging from 0 (no symptoms) to 6 (dead), assessing the degree of disability and dependence after a neurological injury such as stroke or cardiac arrest. A good outcome will be defined as a mRS of 0 to 3 and a poor outcome as 4 to 6.
Results for this outcome have not been posted.
The GOSE is a 8-point scale that is an extension of the Glasgow Outcomes Scale (which is identical to the CPC, only with inverse scores) where the scores 1, 2 and 3 from the CPC score is divided into two.
Results for this outcome have not been posted.
The EQ-5D-5L is a well-established measure of health-related quality of life that is quantified as a utility (i.e. a measure of quality of life between 0 and 1).
Results for this outcome have not been posted.
Collected over Through hospital admission up to 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vasopressin and Methylprednisolone | 214/237 (90.3%) | 0/237 (0%) | 0/237 (0%) |
| Placebo | 233/264 (88.3%) | 0/264 (0%) | 0/264 (0%) |
| Age, Continuous(years) | Vasopressin and Methylprednisolone | Placebo | Total |
|---|---|---|---|
| Mean | 71 ± 13 | 70 ± 12 | 71 ± 13 |
| Sex: Female, Male(Participants) | Vasopressin and Methylprednisolone | Placebo | Total |
|---|---|---|---|
| Female | 89 | 90 | 179 |
| Male | 148 | 174 | 322 |
| Race and Ethnicity Not Collected(Participants) | Vasopressin and Methylprednisolone | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Six months after the publication of the last results, all de-identified individual patient data will be made available for data sharing. Procedures, including re-coding of key variables, will be put in place to allow for complete de-identification of the data. Data will be completely anonymized according to Danish law. All relevant trial-related documents, including the protocol, data dictionary, and the main statistical code, will be shared along with the data. There will be no predetermined end date for the data sharing.
Supporting information: Study protocol, Statistical analysis plan
Access criteria: Data will be available for any research purpose to all interested parties who have approval from an independent review committee and who have a methodological sound proposal as determined by the steering committee of the current trial. Only the methodological qualities and not the purpose or objective of the proposal will be considered. Interested parties will be able to request the data by contacting the principal investigator. Authorship of publications emerging from the shared data will follow standard authorship guidelines from the International Committee of Medical Journal Editors and might or might not include authors from the steering committee depending on the nature of their involvement.
Ran from Sep 2018 to primary completion in Jan 2021, 28 months.
Results were first posted in Jan 2022, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methylprednisolone
Lars Wiuff Andersen